Biomarkers · Inflammation
Soluble Tumor Necrosis Factor Receptor 1 (sTNFR1)
Lower values carry lower risk. Not measured in our NHANES panel; the curve is synthesised from the published association.
Hazard ratio relative to the curve's reference value, as synthesised from the published association.
Published hazard ratio1.30top vs bottom quarter (95% CI 1.05–1.61) · CKD-focused cohorts
Where people sit
Population percentiles (pg/mL) by sex and age band. Cycle or source as recorded in the catalogue.
| Sex | Age | 5th | 25th | Median | 75th | 95th | n | Cycle / source |
|---|---|---|---|---|---|---|---|---|
| All | 20-39 | 684 | 925 | 1,141 | 1,407 | 1,902 | 1,471 | Dong T, Bevan G, Zidar… |
| All | 40-59 | 774 | 1,022 | 1,240 | 1,505 | 1,988 | 1,471 | Dong T, Bevan G, Zidar… |
| All | 60+ | 875 | 1,131 | 1,352 | 1,615 | 2,087 | 1,471 | Dong T, Bevan G, Zidar… |
| All | all | 774 | 1,022 | 1,240 | 1,505 | 1,988 | 1,471 | Dong T, Bevan G, Zidar… |
| Men | all | 796 | 1,046 | 1,265 | 1,529 | 2,010 | 1,471 | Dong T, Bevan G, Zidar… |
| Women | all | 751 | 998 | 1,215 | 1,480 | 1,966 | 1,471 | Dong T, Bevan G, Zidar… |
Sources
- Hazard curve: Synthesized from mortality_association (HR=1.3 quartile_extreme); per-SD log(HR)=0.205. Q4 vs Q1 for sTNFR1; mortality HR ~1.17-1.45 across adjustment models
- Clinical Significance of Serum Soluble TNF Receptor I/II Ratio for the Differential Diagnosis of Tumor Necrosis Factor Receptor-Associated Periodic Syndrome From Other Autoinflammatory Diseases
Map Soluble Tumor Necrosis Factor Receptor 1 (sTNFR1) against another biomarker.